These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 17045087)

  • 1. Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response.
    McDermott DF; Atkins MB
    Semin Oncol; 2006 Oct; 33(5):583-7. PubMed ID: 17045087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma.
    Atkins MB; Regan M; McDermott D
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6342S-6S. PubMed ID: 15448028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
    McDermott DF; Regan MM; Atkins MB
    Clin Genitourin Cancer; 2006 Sep; 5(2):114-9. PubMed ID: 17026799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of metastatic renal cell carcinoma.
    McDermott DF; Atkins MB
    Cancer J; 2008; 14(5):320-4. PubMed ID: 18836337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine therapy for metastatic renal cell carcinoma.
    Bukowski RM
    Semin Urol Oncol; 2001 May; 19(2):148-54. PubMed ID: 11354535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine therapy: a standard of care for metastatic renal cell carcinoma?
    Hutson TE; Quinn DI
    Clin Genitourin Cancer; 2005 Dec; 4(3):181-6. PubMed ID: 16425986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
    McDermott DF
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):716s-720s. PubMed ID: 17255299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
    Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
    Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
    Donskov F
    Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma.
    Redman BG; Hillman GG; Flaherty L; Forman J; Dezso B; Haas GP
    Clin Cancer Res; 1998 Feb; 4(2):283-6. PubMed ID: 9516912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cytokine therapy for metastatic renal cell carcinoma].
    Eto M; Naito S
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1738-44. PubMed ID: 12402423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of metastatic renal cell carcinoma.
    Reeves DJ; Liu CY
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma.
    Clement JM; McDermott DF
    Clin Genitourin Cancer; 2009 Aug; 7(2):E7-9. PubMed ID: 19692326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.
    Acquavella N; Kluger H; Rhee J; Farber L; Tara H; Ariyan S; Narayan D; Kelly W; Sznol M
    J Immunother; 2008; 31(6):569-76. PubMed ID: 18528297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical applications of IL-2.
    Sznol M; Parkinson DR
    Oncology (Williston Park); 1994 Jun; 8(6):61-7; discussion 67, 71, 74-5. PubMed ID: 7521197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer.
    Shablak A; Sikand K; Shanks JH; Thistlethwaite F; Spencer-Shaw A; Hawkins RE
    J Immunother; 2011 Jan; 34(1):107-12. PubMed ID: 21150719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
    Amato RJ; Malya R; Rawat A
    Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
    Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
    Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.